Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers

Area of Science:

• Molecular Biology
• Cancer Biology
• Genomics

Background:

• Cancer cells rely on protein homeostasis, making proteasome inhibitors a key treatment.
• Intrinsic and acquired resistance limit the efficacy of proteasome inhibitors.
• Understanding resistance mechanisms is crucial for improving cancer therapy.

Purpose of the Study:

• To investigate the link between proteasome subunit expression and resistance to proteasome inhibitors.
• To identify novel therapeutic vulnerabilities associated with proteasome dysfunction.
• To characterize the transcriptomic changes accompanying proteasome subunit suppression.

Main Methods:

• Analysis of large-scale cancer cell line and tumor datasets.
• Gene expression profiling and signature analysis.
• Correlation of proteasome subunit levels with patient outcomes and drug response.

Main Results:

• Suppressed expression of 19S proteasome subunits confers intrinsic resistance to proteasome inhibitors.
• Proteasome subunit suppression is linked to poor prognosis in multiple myeloma.
• Transcriptomic remodeling due to proteasome subunit loss creates vulnerabilities to drugs like ABT-263.

Conclusions:

• Imbalances in 19S proteasome regulatory complex composition are a frequent, heritable state in cancer.
• This state confers resistance to proteasome inhibitors and sensitizes cells to other agents.
• Targeting these vulnerabilities offers new therapeutic avenues for resistant cancers.